Skip to main content

Table 5 Subgroup analyses of PLR for OS

From: Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis

 

No.

HR

95% CI

P

I-squared

P H

Ethnicity

 Asian

3

2.01

1.42–2.87

0.000

0.0%

0.623

 Other

3

1.52

1.11–2.09

0.009

0.0%

0.435

Patients status

 PCa

4

2.01

1.42–2.87

0.068

0.0%

0.623

 mCRPC

1

1.41

0.98–2.04

0.068

–

–

 Localized PCa

1

1.87

1.02–3.42

0.043

–

–

Sample size

 ≤ 300

4

1.70

1.32–2.19

0.000

0.0%

0.421

 > 300

2

1.87

1.02–3.42

0.043

–

–

Follow time

 ≤ 30

2

1.49

1.06–2.10

0.022

0.0%

0.425

 > 30

4

1.96

1.42–2.71

0.000

0.0%

0.615

Cut–off

 ≤ 150

2

2.01

1.42–2.87

0.000

0.0%

0.655

 > 150

3

1.52

1.11–2.09

0.009

25.7%

0.261

 No

1

1.00

1.36–2.18

0.000

–

–

Statistical method

 Multivariable

3

1.75

1.16–2.62

0.007

0.0%

0.763

 Univariable

3

1.78

1.23–2.58

0.002

28.7%

0.246

Therapy

 Surgery

2

1.87

1.02–3.42

0.043

–

–

 Chemotherapy

2

1.48

1.09–2.01

0.012

0.0%

0.640

 Radiotherapy

2

2.33

1.46–3.69

0.000

0.0%

0.798

  1. OS, overall survival; PLR, platelet to lymphocyte ratio; mCRPC, metastatic castration-resistant prostate cancer; PCa, prostate cancer; HR, hazard ratio; CI, confidence intervals; PH, heterogeneity of P-value